Brief: NRx Pharmaceuticals Announces Positive Recommendation To Continue Enrollment In The Ongoing Trial Of NRX-101 In Patients With Suicidal Treatment-Resistant Bipolar Depression

NRX Pharmaceuticals

27/03/2023 11:57

March 27 (Reuters) - NRX Pharmaceuticals Inc  NRXP.O :
    * NRX PHARMACEUTICALS ANNOUNCES POSITIVE RECOMMENDATION TO
CONTINUE ENROLLMENT IN THE ONGOING TRIAL OF NRX-101 IN PATIENTS
WITH SUICIDAL TREATMENT-RESISTANT BIPOLAR DEPRESSION
    * NRX PHARMACEUTICALS INC - INDEPENDENT DATA SAFETY
MONITORING
BOARD RECOMMENDED CONTINUATION OF PATIENT ENROLLMENT AS PLANNED
    * NRX PHARMACEUTICALS INC - NO SAFETY OR FUTILITY SIGNALS
WERE
REPORTED IN FIRST 50 PATIENTS
    * NRX PHARMACEUTICALS INC - TRIAL HAS BEEN UPGRADED TO A
PHASE
2B/3 STUDY THAT MAY BE USED FOR A REGISTRATIONAL FILING
    * NRX PHARMACEUTICALS INC - TO DATE, NO DRUG-RELATED SERIOUS
ADVERSE EVENTS HAVE BEEN IDENTIFIED IN CLINICAL TRIALS OF
NRX-101
    * NRX PHARMACEUTICALS INC - EXPECT TOP-LINE DATA FROM PHASE
2B/3
TRIAL IN Q4
    * NRX - TO DISCUSS PATH TO APPROVAL IN PEOPLE WITH SUICIDAL
TREATMENT RESISTANT BIPOLAR DEPRESSION IN BREAKTHROUGH THERAPY
MEETING WITH FDA IN Q2

Source text for Eikon:  ID:nPn1L0HYca 
Further company coverage:  NRXP.O 

 ((Reuters.Briefs@thomsonreuters.com;))